Thomas Lingelbach | Chief Executive Officer |
Peter Buhler | Chief Financial Officer |
Franck Grimaud | Chief Business Officer |
Samir Devani | Rx Securities |
Maury Raycroft | Jefferies |
Max Herrmann | Stifel Financial Corp. |
Evan Wang | Guggenheim Securities |
Jean-Jacques Le Fur | Bryan Garnier |
Franck Grimaud | Chief Business Officer |
Sebastiaan van der Schoot | Kempen & Company |
Good day, and welcome to our quarter one Financial Results and Corporate Update Call. Pleasure to be with you again today. Yeah.
So basically, the quarter one has again been marked by excellent progress on our clinical programs.
We have been able to report further positive Phase II results for our Lyme vaccine candidates, including quite exciting first pediatric data, first ever in the world of Lyme vaccine development.